Sangamo BioSciences | SGMO - Selling And Administration Expenses


Sangamo BioSciences reported $9.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.72B 134M Jun/2026
Bayer EUR 3.96B 267M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
J&J USD 6.42B 381M Jun/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Merck USD 2.89B 219M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 307M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026